Legal Representation
Attorney
Muzamil Huq
USPTO Deadlines
Application History
23 events| Date | Code | Type | Description |
|---|---|---|---|
| Mar 18, 2024 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| Mar 18, 2024 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED |
| Dec 22, 2023 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Dec 22, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Dec 22, 2023 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Aug 15, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Jun 20, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Jun 20, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION |
| May 31, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| May 15, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| May 5, 2023 | RCCK | S | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION |
| Nov 1, 2022 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Nov 1, 2022 | GNSL | S | LETTER OF SUSPENSION E-MAILED |
| Nov 1, 2022 | CNSL | R | SUSPENSION LETTER WRITTEN |
| Sep 23, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Sep 22, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Sep 22, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Mar 22, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Mar 22, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Mar 22, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Mar 16, 2022 | DOCK | D | ASSIGNED TO EXAMINER |
| Sep 30, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Aug 9, 2021 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
Pharmaceutical products, preparations, and substances for the prevention and treatment of cancer, infectious diseases, allergies, mental illnesses, chemotherapy side effects, radiation side effects, transplantation side effects, and viral, metabolic, cardiovascular, vascular, pulmonary, blood, dermatologic, fibrotic, autoimmune, inflammatory, neurodegenerative, neuromuscular, dietary deficiency, hereditary, endocrine, eye, ear, and voice related diseases and disorders; immunotherapies being medical preparations for the prevention and treatment of cancer, infectious diseases, allergies, mental illnesses, chemotherapy side effects, radiation side effects, transplantation side effects, and viral, metabolic, cardiovascular, vascular, pulmonary, blood, dermatologic, fibrotic, autoimmune, inflammatory, neurodegenerative, neuromuscular, dietary deficiency, hereditary, endocrine, eye, ear, and voice related diseases and disorders; chemical platform technology, namely, small molecule compounds being medical preparations for inducing the expression of antioxidant, anti-inflammatory, and cytoprotective proteins in non-malignant tissues, for activating the immune system, for modulating blood flow in ischemic tissues, for upregulating proinflammatory mediators in tumors, and for treating plant diseases
Classification
International Classes
005